3-[5-(2-Methyl-1,3-oxazol)-yl]pyridine | 122829-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[5-(2-Methyl-1,3-oxazol)-yl]pyridine
• 英文别名: 2-Methyl-5-(3-pyridyl)oxazole；2-methyl-5-pyridin-3-yl-1,3-oxazole
• CAS: 122829-71-4
• 化学式: C₉H₈N₂O
• 分子量: 160.175
• InChiKey: VOOGDXKURPLRRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-(三甲硅乙炔基)吡啶 在 甲醇 、 silver hexafluoroantimonate 、 三苯基膦氯金 、 8-ethylquinoline N-oxide 、 potassium carbonate 作用下， 生成 3-[5-(2-Methyl-1,3-oxazol)-yl]pyridine
  参考文献：
  名称：

  Gold-catalyzed oxazoles synthesis and their relevant antiproliferative activities

  摘要：

  Nine 5-aryl-2-methyloxazole derivatives were synthesized via gold-catalyzed alkyne oxidation. All of the compounds have been screened for their antiproliferative activities against MCF-7 cell (human breast carcinoma), A549 cell (human lung carcinoma) and Hela cell (human cervical carcinoma) lines in vitro. The results revealed that compounds 1b, 1c and 1d exhibited strong inhibitory activities against the MCF-7 cell lines (with IC50 values of 4.6, 9.7 and 2.2 mu mol/L, respectively). (C) 2013 Wei-Min He and Jian-Nan Xiang. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2013.06.026

文献信息

• Oxazoles and thiazoles for the treatment of senile dementia
  申请人：Merck Sharpe & Dohme Ltd.

  公开号：US05324723A1

  公开（公告）日：1994-06-28

  1,3-Oxazole and 1,3-thiazole compounds of formula I, and their pharmaceutically acceptable salts and prodrugs: ##STR1## wherein X represents oxygen or sulphur; R.sup.1 represents a non-aromatic azacyclic or azabicyclic ring system.

  1,3-Oxazole和1,3-噻唑化合物的化学式I，以及它们的药用盐和前药：其中X代表氧或硫；R.sup.1代表非芳香性的氮杂环或氮杂双环环系统。
• Nitrogen-containing 5-membered ring compound
  申请人：Yasuda Kosuke

  公开号：US20080153821A1

  公开（公告）日：2008-06-26

  The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: wherein symbols in the formula have the following meanings; A: —CH 2 — or —S—, B: CH or N, R 1 : H, a lower alkyl group, etc., X: a single bonding arm, —CO—, -Alk-CO—, —COCH 2 —, -Alk-O—, —O—CH 2 —, —SO 2 —, —S—, —COO—, —CON(R 3 )—, -Alk-CON(R 3 )—, —CON(R 3 )CH 2 —, —NHCH 2 —, etc., R 3 : hydrogen atom or a lower alkyl group, Alk: a lower alkylene group, and R 2 : (1) a cyclic group which may be substituted, (2) a substituted amino group, etc., provided that when X is —CO—, then B is N, or a pharmaceutically acceptable salt thereof.

  本发明提供一种由式[I]表示的脂肪族氮含有5元环化合物，其中式中符号的含义如下：A：—CH2—或—S—，B：CH或N，R1：H、低碳基等，X：一个单键臂、—CO—、-Alk-CO—、—COCH2—、-Alk-O—、—O—CH2—、—SO2—、—S—、—COO—、—CON(R3)—、-Alk-CON(R3)—、—CON(R3)CH2—、—NHCH2—等，R3：氢原子或低碳基，Alk：低碳亚烷基，以及R2：（1）一个可能被取代的环状基团，（2）一个取代的氨基团等，前提是当X为—CO—时，B为N，或其药学上可接受的盐。
• Lincomycin Derivatives and Antimicrobial Agents Comprising the Same as Active Ingredient
  申请人：Umemura Eijirou

  公开号：US20090156512A1

  公开（公告）日：2009-06-18

  This invention provides compounds of formula (I) or its pharmacologically acceptable salt or solvate, wherein A represents aryl or a monocyclic or bicyclic heterocyclic group, R 1 represents a halide, nitro, substituted C 1-6 alkyl, optionally substituted amino, C 1-6 alkyloxycarbonyl, optionally substituted aryl, a heterocyclic group, or heterocyclic carbonyl, R 2 represents a hydrogen atom or C 1-6 alkyl, R 3 represents C 1-6 alkyl, all of R 4 , R 5 , and R 6 represent a hydrogen atom, R 7 represents C 1-6 alkyl, m is 1 or 2, and n is 1. The compounds are novel lincomycin derivatives having a potent activity against resistant pneumococci. The compounds can be used as an antimicrobial agent and are useful for preventing or treating bacterial infectious diseases.

  本发明提供了式（I）的化合物或其药理学上可接受的盐或溶剂，其中A代表芳基或单环或双环杂环基，R1代表卤素、硝基、取代的C1-6烷基、可选取代的氨基、C1-6烷氧羰基、可选取代的芳基、杂环基或杂环羰基，R2代表氢原子或C1-6烷基，R3代表C1-6烷基，R4、R5和R6均代表氢原子，R7代表C1-6烷基，m为1或2，n为1。这些化合物是新型的林可霉素衍生物，对耐药性肺炎球菌具有强大的活性。这些化合物可以用作抗微生物剂，并且对于预防或治疗细菌感染性疾病是有用的。
• INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20210387986A1

  公开（公告）日：2021-12-16

  Disclosed herein, inter alia, are inhibitors of integrin alpha 2 beta 1 and methods of using the same.
• US5324723A
  申请人：——

  公开号：US5324723A

  公开（公告）日：1994-06-28